U.S., Feb. 8 -- ClinicalTrials.gov registry received information related to the study (NCT06815666) titled 'BAL Fluid Biomarkers in Sarcoma' on Jan. 26.
Brief Summary: This is a single-centre, Phase II, prospective study designed to assess BALF and TA-derived biomarkers in relation to metastatic burden in STS patients. BALF and TA samples will be collected during routine bronchoscopy performed as part of standard care at Toronto General Hospital (TGH). Additionally, tissue samples of lung metastases and adjacent normal lung will be collected and used to correlate the identified biomarkers.
Study Start Date: April 01
Study Type: INTERVENTIONAL
Condition:
Soft Tissue Sarcoma (STS)
Bronchoalveolar Lavage (BAL)
Bronchoalveolar Lavage Fluid...